Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives DOI Open Access
Valentino Martelli, Joana Vidal, Sílvia Salvans

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1461 - 1461

Published: April 26, 2025

Peritoneal carcinomatosis (PC) represents a challenge in the management of metastatic colorectal cancer (mCRC) because difficulties diagnosis, tumor burden assessment, and selecting optimal treatments. A critical limitation is lack robust prognostic predictive biomarkers, largely relying on serum markers (e.g., carcinoembryonic antigen) or peritoneal index (PCI) for disease extent. Circulating DNA (ctDNA)-genomic fragments shed by cells into bloodstream-is now recommended international guidelines mCRC management. Its potential extends to PC, where it may enhance diagnostic, therapeutic, follow-up strategies. However, PC from CRC (PC-CRC) associated with lower ctDNA levels detection rates compared other sites, posing its clinical utility. To address these limitations, fluid analysis has emerged as promising alternative, (ptDNA) detected at higher concentrations this anatomical space. Integrating ptDNA offer deeper understanding PC-CRC biology provide more precise tools managing complex disease. This approach revolutionize treatment paradigm PC-CRC, bringing precision medicine even subgroup patients traditionally poor outcomes. review aims evaluate prognostic, therapeutic implications highlighting current limitations future directions.

Language: Английский

Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives DOI Open Access
Valentino Martelli, Joana Vidal, Sílvia Salvans

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1461 - 1461

Published: April 26, 2025

Peritoneal carcinomatosis (PC) represents a challenge in the management of metastatic colorectal cancer (mCRC) because difficulties diagnosis, tumor burden assessment, and selecting optimal treatments. A critical limitation is lack robust prognostic predictive biomarkers, largely relying on serum markers (e.g., carcinoembryonic antigen) or peritoneal index (PCI) for disease extent. Circulating DNA (ctDNA)-genomic fragments shed by cells into bloodstream-is now recommended international guidelines mCRC management. Its potential extends to PC, where it may enhance diagnostic, therapeutic, follow-up strategies. However, PC from CRC (PC-CRC) associated with lower ctDNA levels detection rates compared other sites, posing its clinical utility. To address these limitations, fluid analysis has emerged as promising alternative, (ptDNA) detected at higher concentrations this anatomical space. Integrating ptDNA offer deeper understanding PC-CRC biology provide more precise tools managing complex disease. This approach revolutionize treatment paradigm PC-CRC, bringing precision medicine even subgroup patients traditionally poor outcomes. review aims evaluate prognostic, therapeutic implications highlighting current limitations future directions.

Language: Английский

Citations

0